Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-03-01

Clinical Trial Update: A Study of Tadalafil for Duchenne Muscular Dystrophy [Phase 3]

View source ↗

Summary

Phase 3 trial for tadalafil in Duchenne muscular dystrophy was terminated; results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TADALAFIL (TADALAFIL)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Muscular Dystrophy, Duchenne | Phase 3 | Status: TERMINATED | Results posted: 2017-03-01